Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Two papers have shown in mouse tumour models that targeting PI3Kγ in myeloid cells can reduce immune suppression and increase the efficacy of immune checkpoint inhibitors.
Skauet al. demonstrate that the actin nucleating protein FMN2 generates a perinuclear actin and focal adhesion-based structure to protect the nucleus from damage during cell migration through confining 3D microenvironments.
Schereret al. show that analysis of circulating tumour DNA can provide prognostic information and predict relapse in patients with diffuse large B-cell lymphoma.
This Review discusses the molecular processes and clonal evolution that lead to myelodysplastic syndrome (MDS) and secondary acute myeloid leukaemia, highlighting the ways in which these insights are shaping the clinical management of MDS.
This Review summarizes progress in applying nanotechnology to cancer treatment and discusses the challenges of clinical translation and opportunities to develop more effective nanotherapeutics through our increasing understanding of tumour biology and nano–bio interactions.
The four tissue inhibitors of metalloproteinases (TIMPs) regulate proteolysis of a vast range of matrix and cell surface proteins, affecting tumour architecture and cell signalling. This Review article analyses the role of TIMPs in cancer and their potential as targets and biomarkers.
This Opinion article discusses many controversial issues surrounding the connections of progestogens, which stimulate the progesterone receptor, to breast cancer risk and their possible therapeutic use in breast cancer.
Ovarian cancer comprises a broad range of histologically and genetically different tumours. In this Opinion article, Karneziset al. explore the different origins of ovarian cancers and how these contribute to our understanding of genetic and environmental risk to better prevent and treat these tumours.
